3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
103
Lymphoma, Large B-Cell, Diffuse
80
Leukemia, Myeloid, Acute
74
Multiple Myeloma
70
Breast Neoplasms
70
Lymphoma, Non-Hodgkin
62
Lymphoma
61
Leukemia, Lymphocytic, Chronic, B-Cell
53
Burkitt Lymphoma
52
Recurrence
51
Myelodysplastic Syndromes
50
Lymphoma, Follicular
50
Lymphoma, B-Cell
47
Leukemia
43
Triple Negative Breast Neoplasms
40
Lymphoma, Mantle-Cell
38
Neoplasms
37
Hodgkin Disease
34
Melanoma
33
Lymphoma, B-Cell, Marginal Zone
32
Hematologic Neoplasms
31
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
29
Neuroblastoma
28
Ovarian Neoplasms
26
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
22
Neoplasm Metastasis
22
Pancreatic Neoplasms
21
Leukemia, Biphenotypic, Acute
21
Sarcoma
18
Myeloproliferative Disorders
17
Interventions
Bevacizumab
2
tislelizumab
1
fludarabine
1
codrituzumab
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Simpson-Golabi-Behmel syndrome
×
Cyclophosphamide
×
1 year
×
Clear all
NCT07500220
2026-03-30
DUET-HCC
Beijing Biotech
Phase 1/2
Recruiting
30 enrolled